Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

V disease and is administered by intramuscular injection. The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease. The first dose of Synagis should be administered prior to commencement of the RSV season, which usually starts in the fall and runs through the spring. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Very rare cases (<1 per 100,000 patients) of anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. Cases of anaphylaxis were reported following re-exposure to Synagis and rare severe hypersensitivity reactions occurred on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reaction occurs, caution should be used on re-administration of Synagis.

In clinical trials, the most common adverse events occurring at least one percent more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever and rhinitis. Cyanosis and arrhythmia were seen in children with CHD.

The pivotal trial for Synagis was called the IMpact trial and comprised a total of 1,502 children who were randomized (500 placebo, 1,002 Synagis) in a double-blind, placebo-controlled protocol where 1,486 children completed the study's follow-up.

In the IMpact trial, monthly prophylaxis with Synagis via intramuscular injections was associated with a 55-percent reduction in hospitalization as a result of RSV (p=<0.001). Reductions were observed in both children with bronchopulmonary dysplasia (38 percent reduction) and premature children without BPD (78 percent reduction). Approximately 50 percent of the
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... KUALA LUMPUR, Malaysia , April 20, 2015 /PRNewswire/ ... 2015, resulting in a scarcity of opportunities for generic ... drug manufacturers in the region are looking beyond the ... the quality of existing drugs. Certain established generic manufacturers ... research and development of new molecules, although the impact ...
(Date:4/20/2015)... , April 21, 2015  Following is the ... LIFESAVING MEDICINE ... most important medicines — insulin —became available for general ... millions of people suffering from diabetes. Insulin is a ... the processing of carbohydrates in the human body. It ...
(Date:4/20/2015)... -- This report analyzes the worldwide markets for Breast Pumps ... Pumps, and Powered Breast Pumps. The report provides separate comprehensive ... Japan , Europe , ... and forecasts are provided for the period 2014 through 2020. ... Market data and analytics are derived from primary and secondary ...
Breaking Medicine Technology:Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 2Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 4Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 5U.S. Census Bureau Daily Feature for April 21 2World Breast Pumps Industry 2World Breast Pumps Industry 3World Breast Pumps Industry 4World Breast Pumps Industry 5World Breast Pumps Industry 6World Breast Pumps Industry 7World Breast Pumps Industry 8World Breast Pumps Industry 9World Breast Pumps Industry 10World Breast Pumps Industry 11World Breast Pumps Industry 12World Breast Pumps Industry 13World Breast Pumps Industry 14
... Inc. (Nasdaq: STRM ) today announced financial ... ended January 31, 2011. Highlights for the ... purchase contracts for add-on licenses with existing clients totaling ... recognized during the quarter; Company completed and ...
... N.J., April 12, 2011 Novartis Pharmaceuticals Corporation ... Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... treatment of patients with advanced neuroendocrine tumors (NET) ... provided after presentation of data from the everolimus ...
Cached Medicine Technology:Streamline Health® Solutions Reports Q4 Results 2Streamline Health® Solutions Reports Q4 Results 3Streamline Health® Solutions Reports Q4 Results 4Streamline Health® Solutions Reports Q4 Results 5Streamline Health® Solutions Reports Q4 Results 6Streamline Health® Solutions Reports Q4 Results 7Streamline Health® Solutions Reports Q4 Results 8Streamline Health® Solutions Reports Q4 Results 9Streamline Health® Solutions Reports Q4 Results 10Streamline Health® Solutions Reports Q4 Results 11Streamline Health® Solutions Reports Q4 Results 12Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
(Date:4/20/2015)... When author Faith Canter was diagnosed ... if nothing could wake her up - and she wasn’t ... are currently living with CFS. , Rather than accepting her ... Living a Life Less Toxic : The Whole Life Approach ... Happier, Healthier Life for You, Your Family and Our Planet.” ...
(Date:4/20/2015)... Heritage Woods of Centralia, a Gardant ... and Dine-and-Dash Spaghetti Dinner from 4 p.m. to 6 ... located in Centralia, Illinois, houses senior living apartments, affordable ... 55 and older. , Guests are invited to tour ... options for seniors. After the tours, they can take ...
(Date:4/20/2015)... 2015 Construction has reached completion ... Draft, an independent, nonprofit community hospital with existing ... The project was an ongoing collaboration between Timmons ... is expected to provide additional employment opportunities for ... Highway, the new facility features physician offices, a ...
(Date:4/20/2015)... April 21, 2015 Using Quality by ... Speed Production and Improve Compliance , **FDAnews Webinar**, May ... http://www.fdanews.com/qualitybydesign , The life sciences industries are ... to do more with less. Mergers, acquisitions, the ... to finds ways to speed up production while still ...
(Date:4/20/2015)... Is it possible to create measures of ... the local needs of the providers, payers and patients who ... over the past year by the Hutchinson Institute for Cancer ... Center in Seattle, Washington. , In a new commentary ... Journal of Managed Care, HICOR Director Scott Ramsey, MD, ...
Breaking Medicine News(10 mins):Health News:New book by Faith Canter offers guide to banishing toxins 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:Augusta Health Construction Wraps Up at Stuarts Draft 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 3Health News:Creating Value Metrics in Cancer Care From the Bottom Up 2Health News:Creating Value Metrics in Cancer Care From the Bottom Up 3
... to a major disaster should focus on three consecutive missions: ... aid, according to research presented Sunday, Oct. 3, at the ... San Francisco. In January, within 24 hours of ... States Naval Ship (USNS) Comfort was deployed to Haiti. With ...
... was higher among adults in Puerto Rico compared to ... was lower, according to data presented at the Third ... held Sept. 30 to Oct 3, 2010. Genetic ... and other venues, providing individual access to genetic tests ...
... Hopkins Medicine, Johns Hopkins scientists have discovered a way to ... proteins in mice, a discovery that could have implications for ... such as peanuts and milk. The findings, published online ... the body could be trained to tolerate food allergies that ...
... instrument due to fly aboard NASA,s James Webb Space Telescope ... facilities at the Rutherford Appleton Laboratory (RAL) in the United ... to areas of investigation as diverse as the first light ... other stars. "The start of space simulation testing ...
... A UC Irvine infectious disease specialist has received a ... methods to prevent staph infections in people who harbor MRSA ... Agency for Healthcare Research & Quality awarded Huang the grant ... American Recovery & Reinvestment Act of 2009. CHOICE grants will ...
... Boston Medical Center (BMC) doctors have proven the ... tool that assesses the cleanliness of the colon during ... of the journal Gastrointestinal Endoscopy , demonstrates the ... to rate colon cleanliness during colonoscopy. Audrey ...
Cached Medicine News:Health News:Operation Unified Response: 3 phases of disaster care in Haiti 2Health News:Adults in Puerto Rico aware of genetic testing, but use remains low 2Health News:Johns Hopkins researchers turn off severe food allergies in mice 2Health News:NASA's Webb telescope MIRI instrument takes one step closer to space 2Health News:NASA's Webb telescope MIRI instrument takes one step closer to space 3Health News:NASA's Webb telescope MIRI instrument takes one step closer to space 4Health News:UCI gets major funding to study ways of preventing drug-resistant staph infections 2Health News:Boston Medical Center research study validates the Boston Bowel Preparation Scale 2
... SureFlex™ line of reusable and autoclavable Lithotripsy ... This revolutionary and patented termination method accepts ... In the unlikely event you do manage ... face absolutely prevents damage to your laser ...
ELVeS™ (Endo Laser Vein System) from biolitec is a versatile, easy to use & complete system that allows you to treat all conditions resulting from venous incompetence. (ELVeS has FDA clearance ...
Up-tapered output compresses NA to give low NA fiber performance on high NA fiber stock....
One piece, 100% fused silica construction offers low scatter and high efficiency...
Medicine Products: